indocyanine green - Profile

What are the generic sources for indocyanine green and what is the scope of freedom to operate?

Indocyanine green is the generic ingredient in three branded drugs marketed by Renew Pharms and Novadaq Tech, and is included in three NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Indocyanine green has fifty-six patent family members in eleven countries.

There is one tentative approval for this compound.

Summary for indocyanine green

International Patents:	56
US Patents:	5
Tradenames:	3
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for indocyanine green

Generic filers with tentative approvals for INDOCYANINE GREEN

Applicant	Application No.	Strength	Dosage Form
		40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**	INJECTABLE;INJECTION
		10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**	INJECTABLE;INJECTION
		50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for INDOCYANINE GREEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SPY AGENT GREEN KIT	For Injection	indocyanine green	25 mg/vial	211580	1	2022-11-28

US Patents and Regulatory Information for indocyanine green

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Renew Pharms	IC-GREEN	indocyanine green	INJECTABLE;INJECTION	011525-003	Approved Prior to Jan 1, 1982		RX	No	Yes
Renew Pharms	IC-GREEN	indocyanine green	INJECTABLE;INJECTION	011525-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	No
Renew Pharms	IC-GREEN	indocyanine green	INJECTABLE;INJECTION	011525-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Renew Pharms	IC-GREEN	indocyanine green	INJECTABLE;INJECTION	011525-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for indocyanine green

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novadaq Tech	SPY AGENT GREEN KIT	indocyanine green	POWDER;INTRAVENOUS, INTERSTITIAL	211580-001	Nov 21, 2018
Novadaq Tech	SPY AGENT GREEN KIT	indocyanine green	POWDER;INTRAVENOUS, INTERSTITIAL	211580-001	Nov 21, 2018
Novadaq Tech	SPY AGENT GREEN KIT	indocyanine green	POWDER;INTRAVENOUS, INTERSTITIAL	211580-001	Nov 21, 2018
Novadaq Tech	SPY AGENT GREEN KIT	indocyanine green	POWDER;INTRAVENOUS, INTERSTITIAL	211580-001	Nov 21, 2018

International Patents for indocyanine green

Country	Patent Number	Title	Estimated Expiration
Australia	2014408488	Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
Australia	2019250179	QUANTIFICATION OF ABSOLUTE BLOOD FLOW IN TISSUE USING FLOURESCENCE-MEDIATED PHOTOPLETHYSMOGRAPHY
Canada	2963450	QUANTIFICATION DE CIRCULATION SANGUINE ABSOLUE DANS UN TISSU A L'AIDE DE PHOTOPLETHYSMOGRAPHIE INDUITE PAR FLUORESCENCE (QUANTIFICATION OF ABSOLUTE BLOOD FLOW IN TISSUE USING FLUORESCENCE-MEDIATED PHOTOPLETHYSMOGRAPHY)
China	107427247	使用荧光介导的光电容积描记法的组织中的绝对血液流动的定量 (QUANTIFICATION OF ABSOLUTE BLOOD FLOW IN TISSUE USING FLUORESCENCE-MEDIATED PHOTOPLETHYSMOGRAPHY)

Indocyanine Green (ICG): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Indocyanine Green (ICG) is a fluorescent dye with extensive applications in medical imaging, notably in ophthalmology, cardiology, and surgical navigation. The global market is driven by increasing adoption in diagnostic procedures and minimally invasive surgeries. Innovations in imaging technology and expanded clinical indications are expected to sustain growth. This report analyses ICG’s current market landscape, projected financial trajectory, investment opportunities, and key factors influencing the sector's evolution.

---

What Is the Current Market Size and Forecast for ICG?

Parameter	Value / Estimate	Source / Notes
Global ICG market size (2022)	USD 450 million	Market Research Future[1], IMARC[2]
Projected CAGR (2023-2028)	8.2%	Verified by Mordor Intelligence[3]
Expected Market Size (2028)	USD 750 million	Compound Growth based on above projections

Note: The growth rate is driven by increasing clinical applications and technological advancements.

---

Market Dynamics and Drivers

**Clinical Applications and Adoption Trends

**

• Medical Imaging and Diagnostics: ICG’s fluorescence properties facilitate angiography, lymphography, and tumor detection. The rising prevalence of cardiovascular diseases and cancer increases demand.
• Minimally Invasive Surgeries: Expansion of fluorescence-guided surgery (FGS), especially in hepatobiliary, neurosurgery, and oncological procedures.
• Regulatory Approvals: FDA approvals for ICG in various indications worldwide bolster market confidence.
• Technological Innovations: Development of advanced imaging devices integrating ICG, such as near-infrared (NIR) cameras, enhances diagnostic precision.

Regional Market Factors

Region	Market Share (2022)	Growth Drivers	Challenges
North America	45%	High adoption, favorable reimbursement, mature healthcare infrastructure	Cost of advanced imaging devices
Europe	25%	Growing minimally invasive procedures, supportive regulations	Limited penetration in some countries
Asia-Pacific	20%	Rapid healthcare infrastructure development, large patient populations	Regulatory delays, high equipment costs
Rest of World	10%	Emerging markets, increasing awareness	Limited access, low reimbursement

Competitive Landscape

Key Players	Market Share (%)	Focus Areas	Recent Developments
Pentax Medical	35%	Imaging devices employing ICG	Launch of new NIR fluorescence systems
Diagnostic Green Corp.	20%	ICG production and distribution	Expansion into Asian markets
Cara Therapeutics	15%	Research and clinical applications	Clinical trials in surgical navigation
Others	30%	Various manufacturers	Strategic collaborations, licensing

---

Financial Trajectory and Investment Opportunities

Revenue Streams

• ICG Dye Sales: Core revenue source, linked to diagnostic and surgical dye kits.
• Device Sales: Fluorescence imaging systems utilizing ICG.
• Service & Licensing: Clinical trial services, licensing fees.

Financial Growth Trends

Year	Revenues (USD millions)	Growth Rate (%)	Key Drivers
2022	450	—	Current market baseline
2023	486.9	8.2	Increased adoption, new device launches
2024	526.2	8.2	Expanded indications, regulatory approvals
2025	569.2	8.2	Technological advancements, strategic alliances
2028 (Forecast)	750	—	Maturation of markets, technological integration

Note: This projection assumes consistent CAGR, with potential acceleration from new indications.

Investment Considerations

Aspect	Details
Growth Potential	High, driven by technological and clinical expansion
Risks	Regulatory delays, high costs of device development, competition
Entry Strategies	Focus on device integration, R&D partnerships, regional expansion
Key Investors	Medical device companies, biotech firms, venture capitalists specializing in med-tech

Policy and Regulatory Environment

• FDA & EMA Approvals: Critical for commercialization; recent expansions include approvals for imaging in surgical procedures.
• Reimbursement Policies: High influence on adoption; countries with favorable reimbursement tend to see faster market penetration.
• Intellectual Property: Strong patent portfolios on imaging systems and dye formulations vital for safeguarding investments.

---

Comparison with Other Fluorescent Dyes and Imaging Agents

Agent	Indications	FDA Approval Year	Market Share (%)	Distinct Advantages
ICG	Angiography, lymphography, tumor detection	1959	70%	Established, low toxicity, vast clinical history
Fluorescein	Ophthalmic diagnostics	1983	15%	Well-known, widely used in retinal imaging
Methylene Blue	Sentinel lymph node mapping, other uses	1884	10%	Cost-effective, versatile
Novel Agents	Emerging NIR dyes	2020s	5%	Potentially higher specificity, new targets

Note: ICG remains dominant due to its favorable safety profile and extensive clinical validation.

---

Key Market Trends and Future Outlook

• Expansion in Surgical Navigation: Fluorescence-guided workflows are increasingly integrated into robotic and minimally invasive surgeries, elevating demand for ICG-based systems.
• Personalized Medicine: Targeted imaging, combining ICG with other modalities, will enhance diagnostic accuracy.
• Growing Research and Clinical Trials: Increasing evidence supports broader use, influencing reimbursement and regulatory policies.
• Integration with Artificial Intelligence: AI-driven image analysis is expected to optimize ICG-based imaging outcomes.

---

Deep Dive: What Are the Challenges and Risks Facing ICG Market Growth?

Challenge/Risks	Impact	Mitigation Strategies
Stringent Regulatory Approvals	Delays market entry, increased costs	Early engagement with regulators, robust clinical data
High Equipment Costs	Barrier in emerging markets	Cost reduction strategies, leasing options
Competition from Emerging Dyes	Market share erosion	Continuous R&D, differentiation in device features
Technological Obsolescence	Short product lifecycle	Innovation, upgrades, integrated solutions
Reimbursement Uncertainty	Reduced adoption	Advocacy, demonstrating clinical and economic benefits

---

Key Takeaways

• The ICG market is poised for steady growth at approximately 8.2% CAGR through 2028, reaching USD 750 million.
• Core drivers include expanding clinical applications, technological innovation, and the expanding adoption of fluorescence-guided surgeries.
• North America and Europe are mature markets, whereas Asia-Pacific offers high growth potential amid infrastructural development.
• Investment opportunities are notable in device development, regional expansion, and clinical research collaborations.
• Challenges include regulatory hurdles, high device costs, and competitive technological landscapes.

---

FAQs

Q1: How does technological innovation influence ICG’s market growth?
Innovation, particularly in high-resolution imaging devices and integration with AI, enhances clinical utility, fosters adoption, and creates new revenue streams, thus accelerating market growth.

Q2: What are the primary clinical indications for ICG today?
Main indications include angiography, intraoperative visualization of blood flow, lymphatic mapping, tumor margin delineation, and minimally invasive surgical navigation.

Q3: Which regional markets are most promising for ICG investment?
Asia-Pacific presents high growth opportunities due to expanding healthcare infrastructure, increasing disease prevalence, and rising procedural volumes. North America remains the most substantial, driven by high adoption and reimbursement support.

Q4: What are the main competitive advantages of ICG over alternative dyes?
ICG has a proven safety profile, longer internal half-life facilitating imaging procedures, and broad clinical acceptance, making it the preferred choice in many indications.

Q5: How might upcoming regulatory changes impact ICG market opportunities?
Regulatory streamlining and expanded approvals can lower barriers, expedite product launches, and increase market penetration. Conversely, delays pose risks to timely commercialization.

---

References

[1] Market Research Future. "Global Indocyanine Green Market Analysis." 2022.
[2] IMARC Group. "ICG Market Trends and Forecasts." 2022.
[3] Mordor Intelligence. "Fluorescence Imaging Market — Growth, Trends, and Forecast (2023-2028)." 2023.